eQcell™ is a is an Ontario-based, Canadian-owned regenerative medicine biotech company based on culture-expanded adult and neonatal stromal cells, so-called mesenchymal stromal cells (MSC).
The company currently offers MSC isolation services for Canadian veterinarians for autologous use in dogs and horses. In these cases, the cells are isolated from adipose tissue of dogs and bone marrow aspirate of horses. Allogenic MSCs are available for use in dogs and horses which do not require any invasive tissue harvesting from the patient prior to treatment. The company also offers individual cell banking of equine cord blood MSCs, referred to as autologous cell-banking.
The company is increasingly focusing on the development of allogenic equine cord blood as well as feline and canine adipose derived MSCs for widespread use in research, clinical trials and ultimately in regulatory approved products.
Through academic partnerships, the company is involved in several in vivo research studies and clinical trials in both horses and dogs using allogenic MSCs for conditions such as equine tendon injuries, equine exercise induced pulmonary hemorrhage (EIPH), equine intra-articular soft tissue injuries (carpal and stifle joints), equine osteochondral repair, equine cartilage resurfacing, and canine osteoarthritis (OA).
Secreted factors from the cells are being investigated for their possible use as in vitro potency assays (predictors of cell function) and therapeutic potential.
Novel blood-based diagnostic tests of early OA using non-coding RNA such as microRNAs are also being pursued to allow detection of joint damage prior to clinical signs.